en-us
📢 Major Announcement: Pharmasaga to List on the Emerging Stock Market on November 27. Shareholders must process the New Share Exchange Notice mailed by Mega Securities in November to protect their rights. Click here for details.

New Drug Innovation,
Opens a New Chapter in Diabetes Treatment

Contact Us
Pharmasaga

About Us

Pharmasaga was established in January 2021 as a spin-off company from the Academia Sinica, transferring the research achievements of Dr. Wen-Chin Yang's laboratory over ten years. PS1 can effectively inhibit the PDIA4 protein, which plays a key role in diabetes, and data shows it can prevent pancreatic cell death and stabilize blood sugar.

About Pharmasaga

Competing for the BIO International Convention Startup Championship

US BIO is the world's premier biotech convention. We are honored to be selected for the Start-up Stadium competition, designed for top-tier technologies. Among the 57 selected teams globally, Pharmasaga is one of only two Asian teams chosen.

Join Pharmasaga

Academia Sinica Spin-off Company

The core technology comes from Dr. Wen-Chin Yang's development platform, aiming to develop novel targets and the first-in-class diabetes drug PS1. We are committed to conducting PS1 clinical trials, with the vision of providing patients with a cure, reducing suffering and social burden.

Investors

Core Technology & Latest Updates

Core Technology

Academia Sinica first discovered and identified the novel diabetes target PDIA4, and utilized a molecular docking technology platform to identify lead compounds that inhibit PDIA4. This led to the development of PS-001, a potential first-in-class small-molecule novel drug for the diabetes market. Our company has obtained the exclusive global license for this technology from Academia Sinica, which serves as the core technology for our drug development.

R&D
Pharmasaga

Clinical Trial Volunteer Recruitment: PS-001 Novel Diabetes Drug

Pharmasaga's core technology PS-001 has entered Phase I clinical trials. This trial is conducted by the Taipei Medical University Hospital, aiming to evaluate safety and potential efficacy.

Core Recruitment Criteria:
  • Age between 18 and 80, gender not restricted
  • Body mass index (BMI) between 18.5 and 40.0 kg/m²
  • No other major diseases or medical history except type 2 diabetes
  • Glycated hemoglobin (HbA1c) between 5.7% and 9.0%, or fasting blood glucose between 100 and 250 mg/dL
  • Willing to comply with all procedures and restrictions of the clinical trial

* This recruitment advertisement has been approved by the Taipei Medical University Joint Institutional Review Board. For detailed information, please click the button below.

Trial Detailed Information

* https://www.taiwanclinicaltrials.tw/tw/recruitment/detail/53?category_id=1&sort_key=execute&sort_arrow=desc

View Detailed Registration Information & Contact Information

* https://e-sub.fda.gov.tw/ClinicalTrialInfo/case-search/PS1-01

News

Contact Us

  • Pharmasaga
  • Phone number : + 886-2-27938665
  • E-mail : contact@pharmasaga.com
  • Address : 22 F.-1, No. 93, Sec. 1, Xintai 5th Rd., Xizhi Dist., New Taipei City 221416, Taiwan (R.O.C.)

Links 

Contact Us